Multimodal Machine Learning Characterization of Solid Tumors

Prostate Cancer Clinical Trial

Official title: Multimodal PET/MRI Machine Learning Approaches for Characterization of Solid Tumors

Status Recruiting

Clinical Trial Summary

This research study wants to develop advanced imaging methods to more accurately characterize prostate cancer or solid tumor aggressiveness.

This observational study involves [18F]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI)

Clinical Trial Description

This is an observational imaging study to evaluate the value of multimodal [18F]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI) for solid tumor characterization and disease staging.

This research study involves:

• Screening visit, and 1-3 study Multimodal [18F]DCFPyL PET/MRI visits

• Two cohorts of participants will be enrolled in this study: primary prostate cancer patients and patients with known or suspected solid tumors (hepatocellular carcinoma, glioma, clear cell renal carcinoma)

• It is expected that about 135 people will take part in this research study

• The PET dye used in this study is called [18F]DCFPyL. [18F]DCFPyL is approved by the U.S. Food and Drug administration (FDA).

• The PET/MRI scanner was approved by the U.S. FDA. ;

Related Conditions & MeSH terms

• Adenocarcinoma
• Adenocarcinoma of Prostate
• Carcinoma
• Carcinoma, Hepatocellular
• Carcinoma, Renal Cell
• Glioma
• Hepatocellular Carcinoma (HCC)
• Prostate Cancer
• Prostatic Neoplasms
• Radical Prostatectomy
• Renal Cell Carcinoma (RCC)

• NCT number: NCT04687969
• Study type: Observational
• Source: Massachusetts General Hospital
• Contact: Ciprian Catana, MD, Ph.D
• Phone: 617-643-4885
• Email: ccatana@mgh.harvard.edu
• Status: Recruiting
• Start date: October 23, 2022
• Completion date: August 31, 2024